These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 30113724)

  • 1. Safety, Pharmacokinetics, and Pharmacodynamics of Multiple Rising Doses of BI 655064, an Antagonistic Anti-CD40 Antibody, in Healthy Subjects: A Potential Novel Treatment for Autoimmune Diseases.
    Schwabe C; Rosenstock B; Doan T; Hamilton P; Dunbar PR; Eleftheraki AG; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    J Clin Pharmacol; 2018 Dec; 58(12):1566-1577. PubMed ID: 30113724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Safety, pharmacokinetics and pharmacodynamics of single rising doses of BI 655064, an antagonistic anti-CD40 antibody in healthy subjects: a potential novel treatment for autoimmune diseases.
    Albach FN; Wagner F; Hüser A; Igel J; Joseph D; Hilbert J; Schoelch C; Padula SJ; Steffgen J
    Eur J Clin Pharmacol; 2018 Feb; 74(2):161-169. PubMed ID: 29127458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Safety, pharmacokinetics and pharmacodynamics of BI 655064 in phase 1 clinical trials in healthy Chinese and Japanese subjects.
    Tsuda Y; Grimaldi C; Huang F; Benediktus E; Yagi N; Padula SJ; Jang IJ; Steffgen J
    Br J Clin Pharmacol; 2021 Apr; 87(4):2000-2013. PubMed ID: 33047859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Phase 1, randomized, double-blind, placebo-controlled, single- and multiple-dose escalation study to evaluate the safety and pharmacokinetics/pharmacodynamics of PF-06835375, a C-X-C chemokine receptor type 5 directed antibody, in patients with systemic lupus erythematosus or rheumatoid arthritis.
    Cohen S; Beebe JS; Chindalore V; Guan S; Hassan-Zahraee M; Saxena M; Xi L; Hyde C; Koride S; Levin R; Lubaczewski S; Salganik M; Sloan A; Stevens E; Peeva E; Vincent MS; Martin DA; Chu M
    Arthritis Res Ther; 2024 Jun; 26(1):117. PubMed ID: 38845046
    [TBL] [Abstract][Full Text] [Related]  

  • 5. First-in-human clinical trial to assess pharmacokinetics, pharmacodynamics, safety, and tolerability of iscalimab, an anti-CD40 monoclonal antibody.
    Espié P; He Y; Koo P; Sickert D; Dupuy C; Chokoté E; Schuler R; Mergentaler H; Ristov J; Milojevic J; Verles A; Groenewegen A; Auger A; Avrameas A; Rotte M; Colin L; Tomek CS; Hernandez-Illas M; Rush JS; Gergely P
    Am J Transplant; 2020 Feb; 20(2):463-473. PubMed ID: 31647605
    [TBL] [Abstract][Full Text] [Related]  

  • 6. First-in-Human Phase 1 Randomized Trial with the Anti-CD40 Monoclonal Antibody KPL-404: Safety, Tolerability, Receptor Occupancy, and Suppression of T-Cell-Dependent Antibody Response.
    Samant M; Ziemniak J; Paolini JF
    J Pharmacol Exp Ther; 2023 Dec; 387(3):306-314. PubMed ID: 37699709
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A randomized, phase 1b study of the pharmacokinetics, pharmacodynamics, safety, and tolerability of bleselumab, a fully human, anti-CD40 monoclonal antibody, in kidney transplantation.
    Vincenti F; Klintmalm G; Yang H; Ram Peddi V; Blahunka P; Conkle A; Santos V; Holman J
    Am J Transplant; 2020 Jan; 20(1):172-180. PubMed ID: 31397943
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An optimally designed anti-human CD40 antibody with potent B cell suppression for the treatment of autoimmune diseases.
    Wu HH; Ralph KL; Sepuldeva E; Hansen G; Li H; Huang ZF; Liu D; Dziegelewski M; Ahlberg J; Frego L; Fogal S; van Tongeren S; Grimaldi C; Litzenberger T; Presky D; Singh S; Brodeur S; Kroe-Barrett R
    Int J Pharm; 2021 Nov; 609():121162. PubMed ID: 34624444
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Safety and tolerability of a humanized rabbit monoclonal antibody (SSS07) in healthy adults: Randomized double-blind placebo-controlled single ascending dose trial.
    Liu C; Dong W; Xia L; Lv J; Jiang D; Wang Q; Wang M; Wu M; Miao J; Tao T; Wang D; Zheng L; Su S; Liu L; Fang Y
    Int Immunopharmacol; 2021 Feb; 91():107263. PubMed ID: 33383447
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, pharmacokinetics and pharmacodynamics of SHR-1703, an innovative long-acting anti-interleukin-5 monoclonal antibody, in healthy subjects: a randomized, double-blind, dose-escalation, placebo-controlled phase I study.
    Yang L; Fang Y; Luo Y; Fu M; Shen K; Luo Z
    Expert Opin Investig Drugs; 2024 Jul; 33(7):741-752. PubMed ID: 38805242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacokinetics, pharmacodynamics and safety of a human anti-IL-6 monoclonal antibody (sirukumab) in healthy subjects in a first-in-human study.
    Xu Z; Bouman-Thio E; Comisar C; Frederick B; Van Hartingsveldt B; Marini JC; Davis HM; Zhou H
    Br J Clin Pharmacol; 2011 Aug; 72(2):270-81. PubMed ID: 21392075
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Safety and tolerability of an anti-CD19 monoclonal antibody, MEDI-551, in subjects with systemic sclerosis: a phase I, randomized, placebo-controlled, escalating single-dose study.
    Schiopu E; Chatterjee S; Hsu V; Flor A; Cimbora D; Patra K; Yao W; Li J; Streicher K; McKeever K; White B; Katz E; Drappa J; Sweeny S; Herbst R
    Arthritis Res Ther; 2016 Jun; 18(1):131. PubMed ID: 27267753
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel CRTH2 Antagonist BI 1021958 at Single Oral Doses in Healthy Men and Multiple Oral Doses in Men and Women With Well-Controlled Asthma.
    Fowler A; Koenen R; Hilbert J; Blatchford J; Kappeler D; Benediktus E; Wood C; Gupta A
    J Clin Pharmacol; 2017 Nov; 57(11):1444-1453. PubMed ID: 28609567
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-IL-7 receptor α monoclonal antibody (GSK2618960) in healthy subjects - a randomized, double-blind, placebo-controlled study.
    Ellis J; van Maurik A; Fortunato L; Gisbert S; Chen K; Schwartz A; McHugh S; Want A; Santos Franco S; Oliveira JJ; Price J; Coles A; Brown K; Su D; Craigen JL; Yang J; Brett S; Davis B; Cheriyan J; Kousin-Ezewu O; Gray F; Thompson PW; Fernando D
    Br J Clin Pharmacol; 2019 Feb; 85(2):304-315. PubMed ID: 30161291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Preclinical Immunopharmacologic Assessment of KPL-404, a Novel, Humanized, Non-Depleting Antagonistic Anti-CD40 Monoclonal Antibody.
    Muralidharan S; Njenga M; Garron T; Bondensgaard K; Paolini JF
    J Pharmacol Exp Ther; 2022 Apr; 381(1):12-21. PubMed ID: 35078863
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and pharmacodynamics of rontalizumab in patients with systemic lupus erythematosus: results of a phase I, placebo-controlled, double-blind, dose-escalation study.
    McBride JM; Jiang J; Abbas AR; Morimoto A; Li J; Maciuca R; Townsend M; Wallace DJ; Kennedy WP; Drappa J
    Arthritis Rheum; 2012 Nov; 64(11):3666-76. PubMed ID: 22833362
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A first-in-human study of the safety, tolerability, pharmacokinetics and pharmacodynamics of PF-06741086, an anti-tissue factor pathway inhibitor mAb, in healthy volunteers.
    Cardinal M; Kantaridis C; Zhu T; Sun P; Pittman DD; Murphy JE; Arkin S
    J Thromb Haemost; 2018 Sep; 16(9):1722-1731. PubMed ID: 29908043
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety, Tolerability, and Pharmacokinetics of PF-06823859, an Anti-Interferon β Monoclonal Antibody: A Randomized, Phase I, Single- and Multiple-Ascending-Dose Study.
    Neelakantan S; Oemar B; Johnson K; Rath N; Salganik M; Berman G; Pelletier K; Cox L; Page K; Messing D; Tarabar S
    Clin Pharmacol Drug Dev; 2021 Mar; 10(3):307-316. PubMed ID: 33352008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study.
    Kretsos K; Golor G; Jullion A; Hickling M; McCabe S; Shaw S; Jose J; Oliver R
    Clin Pharmacol Drug Dev; 2014 Sep; 3(5):388-95. PubMed ID: 27129012
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-CD40 antibody KPL-404 inhibits T cell-mediated activation of B cells from healthy donors and autoimmune patients.
    Marken J; Muralidharan S; Giltiay NV
    Arthritis Res Ther; 2021 Jan; 23(1):5. PubMed ID: 33407802
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.